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respectively. Each of the three factors and the BG item discrim-
inated between those patients who preferred inhaled insulin and
those who preferred injectable insulin (all p < 0.001). Factors
one and three and the BG item demonstrated the ability to detect
change from baseline (injectable treatment) to following treat-
ment with inhaled insulin (all p < 0.001). Factor analysis and
interscale correlations indicated that the 16 items could be
summed to a total IDSQ score. Cronbach’s alpha for the total
score was 0.93. CONCLUSION: The IDSQ is a reliable and
valid instrument to assess insulin delivery system satisfaction in
patients with type-1 diabetes.
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OBJECTIVES: Public health education is a cornerstone in
primary prevention of diabetes mellitus (DM). However, valid
and reliable tools to evaluate outcomes of DM education among
the general public are lacking. We aim to evaluate the reliability
and validity of the General Diabetes Knowledge Test (GDKT)
for use among subjects with and without DM. METHODS: The
GDKT is a 36-item questionnaire (range 0–100) constructed
based on existing public DM education materials and covers six
content areas: overview, risk factors, symptoms, complications,
management and monitoring (for both Type-1 and 2 DM). To
achieve wide representation, English-speaking subjects (aged >
21) were recruited by convenience sampling at a public health
promotion event. The GDKT was ﬁrst administered to 54 DM
and 42 non-DM subjects. Eighteen subjects voluntarily partici-
pated in retest (all were DM). Internal consistency of GDKT was
assessed using Kuder-Richardson Formula 20 (KRF20). Item dif-
ﬁculty was assessed by calculating the ratio of number of correct
answers to number of respondents, range 0.00 (most difﬁcult) to
1.00 (least difﬁcult) and compared between DM and non-DM
subjects using Students’ t-test. Test-retest reliability was assessed
using intraclass correlation coefﬁcient (ICC). Construct validity
was assessed using a known-group approach where DM subjects
were expected to have higher GDKT scores than non-DM sub-
jects. RESULTS: Internal consistency of GDKT was high (KRF20
= 0.9289). Item difﬁculty ranged from 0.59–0.97 and was sig-
niﬁcantly different (p < 0.05) between subjects with and without
DM for 8 items. Test-retest reliability was moderate (ICC = 0.54,
median = 94.4, range = 72.2–100.0, 95% CI: 0.77). Mean scores
at ﬁrst (91.8 ± 9.83) and second (93.3 ± 1.24) administrations
were not signiﬁcantly different (p = 0.38). As expected, DM sub-
jects reported better mean (±SD) GDKT scores (90.8 ± 11.35)
compared to non-DM subjects (85.7 ± 20.80) although the dif-
ference was not statistically signiﬁcant (p = 0.13). CONCLU-
SION: The internal consistency and construct validity of the
GDKT was demonstrated in this study.
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OBJECTIVES: The aim of this study was evaluate the long-term
costs and clinical outcomes of using either insulin aspart or
human insulin (HI) at mealtimes in patients with type-1 diabetes,
based on the clinical ﬁndings of a multicentre, randomized, open-
label comparative trial in 882 patients, which showed that mean
(±SEM) HbA1c was lower after 12 months with insulin aspart
than with HI (7.78 ± 0.03 versus 7.93 ± 0.05, P = 0.005).
METHODS: Long-term clinical and cost outcomes were esti-
mated using the CORE Diabetes Model, a peer-reviewed, vali-
dated model that employs standard Markov/Monte Carlo
simulation techniques to describe the incidence and progression
of diabetes-related complications. Transition probabilities were
derived from major clinical studies. Published country-speciﬁc
costs, health care resource utilization, clinical data and recom-
mended discount rates were used. A lifetime horizon and third
party payer perspective was taken (direct costs only). Extensive
sensitivity analyses were performed. RESULTS: Discounted
quality-adjusted life expectancy (QALE) was improved by 0.08
to 0.22 years with insulin aspart versus HI in the nine countries
investigated. Lifetime cost savings were observed with insulin
aspart in the Austrian, Dutch, French, and Norwegian settings.
Overall costs were increased with insulin aspart versus HI in
Denmark, Finland, Germany, Spain and Sweden, with incre-
mental cost-effectiveness ratios of DKK20,814, €4434, €9553,
€20,916 and SEK32,541 per QALY gained respectively. CON-
CLUSIONS: Improvements in glycemic control associated with
insulin aspart led to improved QALE due to reduced incidence
of complications versus HI. Insulin aspart was projected to be
either cost-saving or cost-effective compared to HI over patient
lifetimes according to accepted international thresholds.
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OBJECTIVES: Using claims data, develop a measure of vari-
ability in insulin use that could be used as a proxy measure of
non-adherence to insulin. Measure the effect of variability of
insulin use on total and diabetes-attributable health care costs in
a managed care population. METHODS: Using a large managed
care administrative claims database, all patients with a prescrip-
tion for long- or intermediate-acting insulin from January, 2000
through June, 2001 were selected (n = 12,336) from among con-
tinuously eligible patients age 18 years and older. Total insulin
units dispensed with each prescription were computed by multi-
plying quantity (ml) from the claims data and strength (units/ml)
from NDC reference data. Units-per-day were computed for each
prescription pair by dividing units dispensed by the number of
days until the next prescription. A time series of units-per-day
was created for each patient during a one year follow-up period.
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The standard deviation of units-per-day over the year was used
as the proxy measure of non-adherence. Total and diabetes-
attributable costs were computed including insurance payments
and patients’ co-payments. Multivariate log-linear regressions
were estimated for costs using variability in long/intermediate-
acting insulin, diabetes severity, overall comorbidity burden, hos-
pitalization in prior six-months, insulin pump use, concomitant
use of short-acting insulin, oral antidiabetic medications, patient
initiating antidiabetic therapy, insurance plan, and demographic
variables. RESULTS: A total of 11,125 patients had at least three
prescriptions for long-acting or intermediate-acting insulin and
were used in the models. The standard deviation of units-per-day
ranged from zero to 210, with a median of 11 and 20th and 80th
percentiles of ﬁve and 23, respectively. Total costs increased
0.39% and diabetes-attributable costs increased 0.31% for each
unit increase in the standard deviation of insulin units-per-day.
CONCLUSIONS: Increased variability of insulin use increases
total and diabetes-attributable annual costs.
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Electronic medical records (EMR) have been incorporated into
many health care settings to assist physicians in sharing patient
information effectively across health care providers. Most EMRs
were designed to optimize sharing of clinical information and
not to accommodate the needs of health services researchers.
Building a comprehensive database that includes information
from multiple databases and EMR sources can be challenging.
OBJECTIVE: To develop a comprehensive diabetes dataset of
clinical resource utilization information and costs using a com-
munity clinics and hospital based EMR and charge data. This
allows a direct comparison of resource utilization and econom-
ics associated with various anti-diabetic treatments. METHODS:
Prescription order data for patients on anti-diabetic medications
or with a diagnosis of diabetes in 2001–2003 were obtained from
the community clinics EMR system. Other health care informa-
tion was collected from the hospital outpatient clinics and hos-
pital EMR systems. Pertinent health care information included
site of care, procedures performed, laboratory tests results, and
diagnosis. Missing information was retrieved manually from the
EMR chart from physician notes which are not transferred to
the EMR database or imputed from retrieved data sources.
Resource use information was matched to ﬁnancial data based
on patient visit numbers. Professional charges were matched to
each visit based on patient identiﬁer and approximate visitation
date, with Institutional Review Board approval. RESULTS: The
ﬁnal dataset includes pertinent clinical, costs resource utilization
information for patients suffering from diabetes across 810
patients receiving insulin. This dataset was used to determine the
differences in resources and cost differences between different
insulin regimens. CONCLUSION: Integrated data systems
across outpatient and inpatient settings can be very useful in out-
comes research however pulling together information from
various datasets can be challenging.
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OBJECTIVES: The Diabetes Prevention Program (DPP)
excluded subjects at baseline due to multiple disease states. The
objectives of this study were to 1) design a long-term cost-
effectiveness model to evaluate the use of intensive lifestyle inter-
vention to prevent type-2 diabetes (T2DM) based on the DPP
study design; and 2) attempt to project these ﬁndings onto a
more generalized hypothetical population than that studied by
the DPP. METHODS: Markov models were developed based on
the DPP results incorporating the states of normal glucose tol-
erance, impaired glucose tolerance, T2DM and death. Transition
probabilities were derived from DPP and current literature. 
A three-year intervention was assumed with outcomes of 1) a 
three-year duration of effect; and 2) a lifetime duration of effect.
A second set of models, based on a hypothetical, more general-
ized population included higher direct medical control cost of
illness, and US Life Table mortality ﬁgures. RESULTS: Lifestyle
dominated placebo in both models, with the following results
derived for incremental cost-effectiveness ratios: 1) DPP model—
3-year duration = -$6,319/LY; 2) DPP model—lifetime duration
= -$11,804/LY; 3) generalized model—three-year duration =
-$16,064/LY; and 4) generalized model—lifetime duration =
-$19,496/LY. A maximal acceptable cost of intervention per year
for the three-year duration of effect that could be used to main-
tain lifestyle domination was also established. These values were:
1) DPP model—three-year duration = $1820/year; 2) DPP
model—lifetime duration = $6500/year; 3) generalized model—
three-year duration = $2910, and 4) generalized model—lifetime
duration = $9750. CONCLUSION: In this model that examined
an intervention that had little apparent effect on life expectancy,
increasing control cost of illness increased incremental costs and
incremental cost-effectiveness ratios, and ultimately increased
the apparent cost-effectiveness of this preventive treatment.
PDB41
VALIDATION OF THE GERMAN TRANSLATION OF THE
NORFOLK QOL-DN, NERVE FIBER SPECIFIC QUESTIONNAIRE
IN A NATIONAL, MULTICENTER COST OF ILLNESS STUDY
(DIMICO) FOR DIABETIC MICROVASCULAR COMPLICATIONS
IN GERMANY
Vinik EJ1, Paulson J2, Ford-Molvik SL1, Oglesby A3,Watkins J3,
Hayes C3,Vinik AI1
1Eastern Virginia Medical School, Norfolk,VA, USA; 2Center for
Pediatric Research, Norfolk,VA, USA; 3Eli Lilly and Company,
Indianapolis, IN, USA
OBJECTIVE: The objective was to validate the construct of the
German-translated version of the Norfolk QOL-DN by factor
analysis in a German population with ﬁve stages of neuropathy
and correlate the resulting factors with degrees of neuropathy.
METHODS: Conducted in 97 sites in Germany, 186 patients
(type-1 n = 33; type-2 n = 153) with diabetic neuropathy were
assessed and categorized: asymptomatic DN (n = 40); sympto-
matic DN (n = 46); DN with history of foot ulcers (n = 32); DN
with amputations (n = 22); and DN with history of amputations
(n = 46). Data was assessed from completion of two self-
administered HQOL questionnaires: Short Form-12 (SF-12) and
Norfolk QOL-DN, a 47 item nerve ﬁber speciﬁc tool, back and
forward translated from English into German. Factor analysis by
Varimax rotation was performed; relationship of the factors to
stages of complications was conducted using two METHODS:
least squares regression and PLUM. Complication stage was
entered as the dependent variable, with all ﬁve factors as pre-
dictors. RESULTS: Five factors resulted from analysis of this
German neuropathy population (multi-staged), matching factors
from a European study population (mild neuropathy). The ﬁrst
factor (Functional Status/Large Fiber) and third factor Activities
